

MEETING ABSTRACTS

Open Access

Immunohistochemically confirmed HHV-8-related lymphoproliferative disorders in Uganda

Lynnette K Tumwine^{1,3}, Robert Lukande^{1,3}, Weiqiang Zhao^{2,3}, Leona W Ayers^{2,3*}

From 12th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI)

Bethesda, MD, USA. 26-27 April, 2010

Background

Human herpesvirus-8 (HHV-8) infection is endemic in Uganda and has an estimated 36%-60% seroprevalence. This virus is in the oropharynx and peripheral blood of Ugandans with Kaposi's sarcoma, and viremia is increased in those with HIV-1. While Kaposi's sarcoma is widely recognized as both endemic and with HIV epidemic, HHV-8 associated lymphoproliferative disorders have not been previously reported in Uganda. Evidence for these disorders was sought in lymphoma surveys conducted by sub-Saharan African Lymphoma Consortium (SSALC) consortium members in Uganda.

Materials and methods

Samples of 456 malignant lymphoma and adenopathy cases in formalin-fixed paraffin-embedded (FFPE) blocks from the Uganda SSALC and the Uganda AIDS and

Cancer Specimen Resource (ACSR) were examined for morphology and Lana-1 (immunohistochemical, IHC) for diagnosis of HHV-8 lymphoproliferative disorders. Samples were also tested (IHC and in situ hybridization, ISH) using 20 monoclonal antibodies for common NHL antigens, ISH for EBV-encoded RNA, and kappa/lambda light chains (ISH, Ventana, Tucson).

Results

Many but not all of reported HHV-8-related proliferative disorders were identified in this sample population. Those identified and remaining to be identified are listed in Table 1.

Conclusions

HHV-8 proliferative disorders excluding Kaposi's sarcoma are present but generally not recognized by

Table 1 Subtypes

Subtype			N
Castleman's disease	Unicentric varieties	Hyaline vascular variant	2
	Multicentric varieties	Plasma cell variant	1
		Plasmablastic variant	1
		Lymphocyte depleted	1
Plasmablastic lymphoma (HHV-8 negative and positive)			2
Primary effusion lymphoma			
Peripheral T-cell lymphoma			
Diffuse large B-cell lymphoma			
Plasmacytic lymphoproliferative disorder			1
Total			8

*Correspondence: ayers.1@osu.edu

²Department of Pathology, The Ohio State University, Columbus, OH, USA
Full list of author information is available at the end of the article

Ugandan clinicians and pathologists. Disorders are present in Uganda, especially in HIV-positive patients, in association with the high infection rates of both HIV-1 and HHV-8. Recognition is important because HHV-8 infection in HIV-1-positive patients associates with poor prognosis. Familiarity with the clinical presentation and tissue morphology of these disorders will likely result in recognition of the full range of reported HHV-8 proliferative complications. HHV-8-related lymphoma has increased prevalence in the HIV-1 infected. It arises and progresses in the face of highly active antiretroviral therapy immune reconstitution, making recognition of these disorders critical to patient care. We participate in the Sub-Saharan Africa Lymphoma Consortium [<http://www.ssalc.org>] to expand the understanding of HIV/AIDS-related malignancies and viral proliferative disorders in this region of the world.

Acknowledgements

This article has been published as part of *Infectious Agents and Cancer* Volume 5 Supplement 1, 2010: Proceedings of the 12th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI). The full contents of the supplement are available online at <http://www.biomedcentral.com/1750-9378/5?issue=S1>.

Author details

¹Department of Pathology, Makerere University, Kampala, Uganda.

²Department of Pathology, The Ohio State University, Columbus, OH, USA.

³Sub-Saharan Africa Lymphoma Consortium (SSALC/NCI).

Published: 11 October 2010

doi:10.1186/1750-9378-5-S1-A39

Cite this article as: Tumwine *et al.*: Immunohistochemically confirmed HHV-8-related lymphoproliferative disorders in Uganda. *Infectious Agents and Cancer* 2010 **5**(Suppl 1):A39.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

